Evidence map›Paper›PMID 36273380›Full record

ArticleActas espanolas de psiquiatria2022

Confirmatory factor analysis of 20-item toronto alexithymia scale in spanish patients with substance use disorder.

Raul F Palma-Álvarez, Constanza Daigre, Elena Ros-Cucurull, Marta Perea-Ortueta, Pedro Serrano-Pérez, Germán Ortega-Hernández, Josep A Ramos-Quiroga, Lara Grau-López, Carlos Roncero

Abstract read
In one paragraph

Article in Actas espanolas de psiquiatria, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raul F Palma-ÁlvarezDepartment of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain Group of Psychiatry, Mental Health and Addiction, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain Biomedical Network Research Centre on Mental Health (CIBERSAM). Barcelona, Spain.
Constanza DaigreDepartment of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain Group of Psychiatry, Mental Health and Addiction, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain Biomedical Network Research Centre on Mental Health (CIBERSAM). Barcelona, Spain.
Elena Ros-CucurullDepartment of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain Group of Psychiatry, Mental Health and Addiction, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain Biomedical Network Research Centre on Mental Health (CIBERSAM). Barcelona, Spain.
Marta Perea-OrtuetaDepartment of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain Group of Psychiatry, Mental Health and Addiction, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Pedro Serrano-PérezDepartment of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain Group of Psychiatry, Mental Health and Addiction, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Germán Ortega-HernándezDepartment of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain Group of Psychiatry, Mental Health and Addiction, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Josep A Ramos-QuirogaDepartment of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain Group of Psychiatry, Mental Health and Addiction, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain Biomedical Network Research Centre on Mental Health (CIBERSAM). Barcelona, Spain.
Lara Grau-LópezDepartment of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain Group of Psychiatry, Mental Health and Addiction, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain Biomedical Network Research Centre on Mental Health (CIBERSAM). Barcelona, Spain.
Carlos RonceroPsychiatry Service, University of Salamanca Health Care Complex, Institute of Biomedicine, University of Salamanca, Salamanca, Spain Psychiatry Unit, School of Medicine, University of Salamanca, Salamanca, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alexithymia is highly prevalent in patients with substance use disorders (SUDs) and has been implied in SUD pathogenesis and treatment outcomes. However, the psychometric properties of the most-used instrument for evaluating alexithymia (the 20-item Toronto Alexithymia Scale, TAS-20) have been scarcely studied in relation to SUD patients.

Indexed as

Affective SymptomsSubstance-Related DisordersFactor Analysis, StatisticalHumansPsychometrics

Identifiers

PMID36273380
PMCPMC10803880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.